NA
NBIX icon

NewEdge Advisors’s Neurocrine Biosciences NBIX Stock Holding History

NewEdge Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.72M Buy
13,066
+68
+0.5% +$9.02K 0.01% 1185
2025
Q4 		$1.84M Buy
12,998
+672
+5% +$97.4K 0.01% 1115
2025
Q3 		$1.73M Buy
12,326
+1,603
+15% +$217K 0.01% 1092
2025
Q2 		$1.35M Buy
10,723
+3,093
+41% +$355K 0.01% 1125
2025
Q1 		$844K Buy
7,630
+2,747
+56% +$348K 0.01% 1278
2024
Q4 		$667K Sell
4,883
-169
-3% -$20.9K ﹤0.01% 1382
2024
Q3 		$582K Buy
5,052
+1,959
+63% +$269K ﹤0.01% 1379
2024
Q2 		$426K Buy
3,093
+213
+7% +$29.2K ﹤0.01% 1507
2024
Q1 		$397K Buy
2,880
+2,428
+537% +$332K ﹤0.01% 1478
2023
Q4 		$59.6K Buy
452
+404
+842% +$46.5K ﹤0.01% 2172
2023
Q3 		$5.4K Hold
48
– – ﹤0.01% 2784
2023
Q2 		$4.53K Sell
48
-413
-90% -$40.4K ﹤0.01% 2855
2023
Q1 		$46.7K Sell
461
-13,474
-97% -$1.4M ﹤0.01% 2035
2022
Q4 		$1.61M Buy
+13,935
New +$1.63M 0.04% 369

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

NewEdge Advisors's NBIX Position: Q1 2026 in Review

NewEdge Advisors increased its Neurocrine Biosciences (NBIX) stake by 0.52% in Q1 2026, buying an estimated $9.02K and bringing the position to 13,066 shares worth $1.72M. The position accounts for 0.01% of the portfolio, ranked #1185.

NewEdge Advisors first reported a position in NBIX in Q4 2022 and has held it in 14 quarters since. The position peaked at $1.84M in Q4 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • NewEdge Advisors held 13,066 shares of Neurocrine Biosciences worth $1.72M as of Q1 2026.
  • NewEdge Advisors bought 68 Neurocrine Biosciences shares in Q1 2026, an estimated $9.02K.
  • Neurocrine Biosciences made up 0.01% of NewEdge Advisors's portfolio in Q1 2026, its #1185 holding.
  • NewEdge Advisors first reported a position in Neurocrine Biosciences in Q4 2022 and has held it in 14 quarters since.
  • NewEdge Advisors's Neurocrine Biosciences position peaked at $1.84M in Q4 2025.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.